Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Imidapril→

Imidapril Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
89371-37-9
Molecular formula
C20H27N3O6
Molecular weight
405.4 g/mol
Drug class
Angiotensin-converting enzyme (ACE) inhibitorantihypertensive prodrug
Mechanism of action
Imidapril is hydrolysed to the active metabolite imidaprilat, which competitively inhibits angiotensin-converting enzyme. This reduces angiotensin II formation and aldosterone secretion, lowers peripheral vascular resistance and blood pressure, and reduces sodium and water retention.
Indications / reported uses
  • Treatment of essential hypertension.
  • Use in selected patients with chronic heart failure or diabetic nephropathy has been described in clinical studies and depends on local product authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5464343 · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6377&tab=clinical · https://pubmed.ncbi.nlm.nih.gov/17547476/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Imidapril Environmental Risk Assessment (ERA) (the Imidapril ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.